• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results

    8/14/25 4:05:00 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NDRA alert in real time by email

    ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three and six months ended June 30, 2025.

    Business Update

    • Advanced development of TAEUS Liver. ENDRA advanced its product development work with enhancements to the TAEUS Liver system's probe design and proprietary algorithms, which are expected to deliver significantly improved accuracy and repeatability to its liver fat assessments. Initial testing of the new design on a small patient population demonstrated an order-of-magnitude improvement in performance against the gold standard MRI-PDFF measurements. The Company is initiating validation testing of the redesigned probe in a short controlled study to confirm these anticipated performance gains.



    • Focused strategy for TAEUS Liver De Novo submission. The Company further advanced its regulatory strategy regarding its planned De Novo filing for TAEUS Liver with the U.S. Food and Drug Administration (FDA). ENDRA intends to conduct a hypothesis-driven, statistically powered prospective multisite clinical trial enrolling approximately 250 subjects. The final trial design and sample size will be vetted with the FDA, which will assist in achieving the statistical power necessary for the De Novo submission and for publication of results in peer-reviewed journals. The Company expects that the results from the short controlled study will be used for the FDA meetings to confirm the endpoints and protocol. This regulatory alignment is intended to pave the way for the launch of ENDRA's pivotal study by year-end.



    • Expanded the intellectual property portfolio to 85 issued patents globally. During the second quarter of 2025, ENDRA was issued one additional U.S. patent, which covers methods for tuning the thermoacoustic probe. ENDRA's broad intellectual property portfolio provides protection for the TAEUS system with its novel thermoacoustic technology and supports the exploration of licensing opportunities for indications beyond its core focus.



    • Implemented cost reductions while advancing TAEUS development. ENDRA has taken decisive steps to strengthen its financial position over the past nine months. These cost reductions were initiated in the fourth quarter of 2024 and included a decrease in headcount and a streamlining of operations, particularly in general and administrative expenses. As a result, second quarter 2025 operating expenses decreased 42% to $1.2 million compared with $2.2 million in the prior-year period.

    "Our redesigned TAEUS probe represents a major advancement in our ability to non-invasively assess liver health. The early data are extremely encouraging, and our ongoing validation study is an important step toward aligning with the FDA and beginning our pivotal trial later this year," said Alexander Tokman, ENDRA's Chief Executive Officer. "Metabolic diseases—often symptomless until late stages—are the underlying cause of many chronic illnesses, including steatotic liver disease or SLD, which affects more than two billion people worldwide and over 100 million Americans. Due to the absence of practical diagnostic tools for frontline clinicians, SLD remains grossly underdiagnosed. With TAEUS, we aim to bring liver diagnostics into everyday care and enable earlier detection, better treatment decisions and potentially reduce the enormous financial burden metabolic diseases place on the U.S. healthcare system."

    Second Quarter Financial Results

    During 2024, the Company implemented significant cost-reduction initiatives to strengthen its financial position while advancing its strategic priorities. In the second quarter of 2025, the Company's cash burn from operations was $1.1 million, nearly half the $2.1 million reported in the same quarter of 2024.

    Total operating expenses for the second quarter of 2025 were $1.3 million, down 42% year-over-year from $2.2 million, reflecting the impact of cost-optimization measures including streamlined staffing, reduced overhead and a leaner operating model.

    As a result, net loss for the second quarter of 2025 narrowed to $1.2 million from $2.2 million in the year-ago period.

    As of June 30, 2025, ENDRA reported $1.8 million in cash and cash equivalents, providing resources to execute its near-term operational and regulatory milestones.

    About ENDRA Life Sciences Inc.

    ENDRA Life Sciences is the pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. For more information, please visit www.endrainc.com.

    Forward-Looking Statements

    All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as "approximate," "anticipate," "attempt," "believe," "could," "estimate," "expect," "forecast," "future," "goal," "hope," "intend," "may," "plan," "possible," "potential," "project," "seek," "should," "will," "would," or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: expectations with respect to FDA requirements regarding its clinical trials and De Novo submission for its TAEUS liver device; estimates of the timing of future events and anticipated results of its development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches and sales; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; and statements regarding ENDRA's ability to find and maintain development partners. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain FDA and other regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; ENDRA's ability to maintain compliance with Nasdaq listing standards and remain listed on a securities exchange; ENDRA's dependence on its senior management team; market acceptance of ENDRA's technology and the amount and nature of competition in its industry; ENDRA's ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

    [Financial Tables Follow]

    ENDRA Life Sciences Inc.

    Condensed Consolidated Balance Sheets

     

       

     

    Assets

    June 30,

    2025

     

    December 31,

    2024

     

    Current Assets

    (Unaudited)

     

     

     

    Cash

    $

    1,808,574

     

    $

    3,229,480

     

    Prepaid expenses

     

    44,310

     

     

    204,185

     

    Total Current Assets

     

    1,852,884

     

     

    3,433,665

     

    Non-Current Assets

     

     

     

     

    Fixed assets, net

     

    63,419

     

     

    69,281

     

    Right of use assets

     

    519,966

     

     

    578,013

     

    Prepaid expenses, long term

     

    365,417

     

     

    365,417

     

    Other assets

     

    5,986

     

     

    5,986

     

     

     

     

     

     

    Total Assets

    $

    2,807,672

     

    $

    4,452,362

     

         

    Liabilities and Stockholders' Equity

     

     

     

     

    Current Liabilities

     

     

     

     

    Accounts payable and accrued liabilities

    $

    448,419

     

    $

    508,293

     

    Lease liabilities, current portion

     

    128,218

     

     

    96,937

     

    Total Current Liabilities

     

    576,637

     

     

    605,230

     

     

     

     

     

     

    Long Term Debt

     

     

     

     

    Lease liabilities

     

    429,274

     

     

    487,482

     

    Warrant Liability

     

    328,610

     

     

    799,284

     

    Total Long Term Debt

     

    757,884

     

     

    1,286,766

     

     

     

     

     

     

    Total Liabilities

     

    1,334,521

     

     

    1,891,996

     

     

     

     

     

     

    Stockholders' Equity

     

     

     

     

    Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 17,488 and 17,488 shares issued and outstanding, respectively

    -

     

    -

     

    Series B Convertible Preferred Stock, $0.0001 par value; 1,000 shares authorized; no shares issued and outstanding

     

    -

     

     

    -

     

    Series C Preferred Stock, $0.0001 par value; 100,000 shares authorized; no shares issued and outstanding

     

    -

     

     

    -

     

    Common stock, $0.0001 par value; 20,000,000 shares authorized; 752,390 and 536,908 shares issued and outstanding, respectively

     

    74

     

     

    53

     

    Additional paid in capital

     

    107,173,418

     

     

    105,998,412

     

    Stock payable

     

    -

     

     

    -

     

    Accumulated deficit

     

    (105,700,341

    )

     

    (103,438,099

    )

     

     

     

     

     

    Total Stockholders' Equity

     

    1,473,151

     

     

    2,560,366

     

    Total Liabilities and Stockholders' Equity

    $

    2,807,672

     

    $

    4,452,362

     

    ENDRA Life Sciences Inc.

    Condensed Consolidated Statement of Operations

    (Unaudited)

     

     

    Three Months

    Ended

    Three Months

    Ended

    Six Months

    Ended

    Six Months

    Ended

    June 30,

    June 30,

    June 30,

    June 30,

    2025

    2024

    2025

    2024

    Operating Expenses

     

     

     

     

    Research and development

    $

    381,061

     

    $

    716,366

     

    $

    909,746

     

    $

    1,757,892

     

    Sales and marketing

     

    68,834

     

     

    162,952

     

     

    137,825

     

     

    401,612

     

    General and administrative

     

    851,195

     

     

    1,351,535

     

     

    1,722,801

     

     

    2,851,890

     

    Total operating expenses

     

    1,301,090

     

     

    2,230,853

     

     

    2,770,372

     

     

    5,011,394

     

     

     

     

     

     

    Operating loss

     

    (1,301,090

    )

     

    (2,230,853

    )

     

    (2,770,372

    )

     

    (5,011,394

    )

     

     

     

     

     

    Other Income (Expenses)

     

     

     

     

    Other income (expense)

     

    13,066

     

     

    1,700

     

     

    37,456

     

     

    6,541

     

    Warrant expense

     

     

    -

     

     

    -

     

     

    -

     

    Changes in fair value of warrant liability

     

    62,112

     

     

    -

     

     

    470,674

     

     

    -

     

    Gain or Loss on settlement of warrant exercise

     

     

    -

     

     

    -

     

     

    -

     

    Total other expenses

     

    75,178

     

     

    1,700

     

     

    508,130

     

     

    6,541

     

     

     

     

     

     

    Loss from operations before income taxes

     

    (1,225,912

    )

     

    (2,229,153

    )

     

    (2,262,242

    )

     

    (5,004,853

    )

     

     

     

     

     

    Provision for income taxes

     

    -

     

     

    -

     

     

    -

     

     

    -

     

     

     

     

     

     

    Net Loss

    $

    (1,225,912

    )

    $

    (2,229,153

    )

    $

    (2,262,242

    )

    $

    (5,004,853

    )

     

     

     

     

     

    Net loss per share – basic and diluted

    $

    (1.71

    )

    $

    (0.08

    )

    $

    (3.55

    )

    $

    (0.26

    )

     

     

     

     

     

    Weighted average common shares – basic and diluted

     

    717,107

     

     

    15,590

     

     

    637,362

     

     

    10,857

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250814693762/en/

    Company Contact:

    Investor relations

    [email protected]

    www.endrainc.com



    Investor Relations Contact:

    Yvonne Briggs

    Alliance Advisors IR

    (310) 691-7100

    [email protected]

    Get the next $NDRA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NDRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NDRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Market maker/broker-dealer Ubs Group Ag bought 0 shares (SEC Form 4)

    4/A - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    9/5/24 3:28:10 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Ubs Group Ag bought $2,052 worth of shares (3,715 units at $0.55) (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    8/29/24 4:30:01 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results

    ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three and six months ended June 30, 2025. Business Update Advanced development of TAEUS Liver. ENDRA advanced its product development work with enhancements to the TAEUS Liver system's probe design and proprietary algorithms, which are expected to deliver significantly improved accuracy and repeatability to its liver fat assessments. Initial testing of the new design on a small patient population demonstrated an order-of-magnitude improvement in performance against the gold standard MRI-PDFF measurements. The Company

    8/14/25 4:05:00 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA's Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard

    Refinements to probe configuration and proprietary algorithms are expected to drive substantial improvements in MRI-PDFF correlation ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer in imaging technologies for the early detection and monitoring of metabolic liver disease, today announced that its ongoing multisite pilot study has helped to identify several product enhancements to further improve the performance of its TAEUS® Liver system against the gold standard, MRI. These findings are expected to drive substantial improvements to the device's probe design and proprietary algorithms, measurably improving diagnostic accuracy and repeatability. These enhancements are currently being impl

    6/16/25 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

    ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three months ended March 31, 2025. Business Update Incorporating Liver Diagnostics into the Management of Metabolic Disease ENDRA recently announced a strategic pivot to position the company to play an integral role in the treatment of metabolic disease. With a sharpened mission to transform the way steatotic liver disease (SLD) is diagnosed and managed, ENDRA is developing a revolutionary, low-cost, point-of-care diagnostic device—essentially a "blood pressure cuff" for the liver. This strategic shift is aimed squarel

    5/15/25 4:05:00 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Basenese Lou was granted 5,384 shares, increasing direct ownership by 538,400% to 5,385 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    7/1/25 6:26:33 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Harsh Michael was granted 5,384 shares, increasing direct ownership by 269,200% to 5,386 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    7/1/25 6:25:48 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Digiandomenico Anthony was granted 5,384 shares, increasing direct ownership by 9,125% to 5,443 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    7/1/25 6:25:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    SEC Filings

    View All

    SEC Form 10-Q filed by ENDRA Life Sciences Inc.

    10-Q - ENDRA Life Sciences Inc. (0001681682) (Filer)

    8/14/25 4:11:45 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form S-1/A filed by ENDRA Life Sciences Inc.

    S-1/A - ENDRA Life Sciences Inc. (0001681682) (Filer)

    7/25/25 9:28:26 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Life Sciences Inc. filed SEC Form 8-K: Other Events

    8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)

    7/23/25 9:05:39 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ENDRA Life Sciences Inc.

    SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

    6/14/24 4:01:26 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by ENDRA Life Sciences Inc.

    SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

    6/14/24 8:00:02 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by ENDRA Life Sciences Inc.

    SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

    3/10/23 12:18:14 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Leadership Updates

    Live Leadership Updates

    View All

    ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells

    ANN ARBOR, MI / ACCESSWIRE / June 15, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced the appointment of Irina Pestrikova as Senior Director of Finance and Principal Financial Officer. In this new position, Ms. Pestrikova will assume all day-to-day responsibilities previously performed by ENDRA's Chief Financial Officer David Wells, who will leave the Company effective June 18, 2021 to pursue another opportunity.Ms. Pestrikova has supported ENDRA since 2014 and has been actively involved in ENDRA's financial planning and analysis, accounting and SEC reporting functions. Previously, Ms. Pestrikova was a financial analyst at a

    6/15/21 8:35:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Financials

    Live finance-specific insights

    View All

    ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

    ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Update ENDRA made significant progress against many of the new initiatives discussed during the Company's August 22, 2024, conference call to advance its TAEUS Liver device along the development and regulatory process. In addition, ENDRA separately announced today a revamped strategy for TAEUS as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs. ENDRA's prog

    3/31/25 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

    ENDRA Life Sciences Inc. (NASDAQ:NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC ("Nasdaq"). On November 21, 2024, the Company received notification from the Nasdaq Listing Qualifications Department confirming its compliance with Listing Rule 5550(a)(2), thereby meeting Nasdaq's maintenance requirements for listing. "Now that we have regained compliance with Nasdaq's listing requirements, we can focus all our efforts on making progress on our new transformational business strategies, which we reviewed during our August 22nd conference call,

    11/22/24 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

    ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will host a conference call and webcast beginning at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly results, provide an update on recent corporate developments and answer questions. This call was previously scheduled for August 14, 2024. The Company will file its quarterly report on form 10-Q with the SEC as regularly scheduled in the coming days. A press release summarizing its financial and operating results for the second quarter ending on June 30, 2024, will be issued on the day of the call. Participants are encouraged to pre-register

    8/13/24 4:05:00 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care